MYCN and neoplasm: Similarly, recent studies have shown that tumors with an amplified MYCN gene, which is considered the most robust prognostic marker indicating poor outcome for neuroblastoma patients, enhanced glutamine transport and increased glutaminolysis for increased tumor cell growth [10–14].